Session Type: ePosters
Session Title: ePosters
Authors(s): D. Shortridge, J.M. Streit, R.E. Mendes, M. Castanheira
Authors Affiliations(s): JMI Laboratories, United States
Background:
Cefiderocol is a novel siderophore-conjugated cephalosporin with broad activity against Gram-negative bacteria. Cefiderocol was recently approved by the EMA for the treatment of infections caused by Gram-negative bacteria in adult patients with limited treatment options and by the FDA for complicated urinary tract infection (UTI), hospital-acquired bacterial pneumonia, and ventilator-associated bacterial pneumonia. Carbapenem-resistant Enterobacterales (CRE) isolates have disseminated worldwide and present a challenge to treatment. In this study, we analyzed the susceptibility of cefiderocol and comparators tested against European Enterobacterales isolates, including CRE, collected in 2020 as a part of the SENTRY Antimicrobial Surveillance Program.
Methods:
A total of 3,645 Enterobacterales isolates were consecutively collected from 32 European hospitals located in 18 countries during 2020. Susceptibility testing was performed using the broth microdilution method. Cefiderocol was tested in iron-depleted cation-adjusted Mueller-Hinton broth. CLSI/FDA and EUCAST (2020) breakpoints were used. Cefiderocol breakpoints for CLSI and FDA are <=4/8/>=16 mg/L and EUCAST breakpoints are <=2/-/>2 mg/L. CRE were identified as having an MIC >2 mg/L to at least 1 carbapenem. Other agents tested included the beta-lactam/beta-lactamase inhibitor (BL/BLI) combinations: ceftazidime-avibactam, imipenem-relebactam, and meropenem-vaborbactam as well as meropenem and imipenem.
Results:The most common species was Escherichia coli (n=1,648) followed by Klebsiella pneumoniae (n=758). The CRE rate was 3.0% (108/3,645), 88% (95/108) were K. pneumoniae. The majority of isolates were from bloodstream infections (n=1,287), followed by UTI (n=1,107). The susceptibilities and MIC50/90 of cefiderocol and comparators for all isolates and isolate groups are shown in the table. The susceptibilities of all tested agents were >94% against all isolates. For the resistant phenotypes, cefiderocol was the most active agent tested. Against CRE, cefiderocol had higher susceptibility (97.2/88.9%, CLSI/EUCAST) than the BL/BLI combinations, for which susceptibilities ranged from 59.3/67.6% for imipenem-relebactam to 77.8/77.8% ceftazidime-avibactam. Cefiderocol maintained activity against isolates resistant to the BL/BLI combinations, including ceftazidime-avibactam-resistant isolates.
Conclusions:Cefiderocol had broad activity against European Enterobacterales isolates, including those resistant to recently approved BL/BLI combinations. These data suggest that cefiderocol is an important option for the treatment of infections caused by CRE and other resistant pathogens.
Keyword(s): CRE, cefiderocol, European surveillanceCOI Institutional Grants: Yes
COI Other: This study was performed by JMI Laboratories and supported by Shionogi, which included funding for services related to preparing this abstract.
Session Type: ePosters
Session Title: ePosters
Authors(s): D. Shortridge, J.M. Streit, R.E. Mendes, M. Castanheira
Authors Affiliations(s): JMI Laboratories, United States
Background:
Cefiderocol is a novel siderophore-conjugated cephalosporin with broad activity against Gram-negative bacteria. Cefiderocol was recently approved by the EMA for the treatment of infections caused by Gram-negative bacteria in adult patients with limited treatment options and by the FDA for complicated urinary tract infection (UTI), hospital-acquired bacterial pneumonia, and ventilator-associated bacterial pneumonia. Carbapenem-resistant Enterobacterales (CRE) isolates have disseminated worldwide and present a challenge to treatment. In this study, we analyzed the susceptibility of cefiderocol and comparators tested against European Enterobacterales isolates, including CRE, collected in 2020 as a part of the SENTRY Antimicrobial Surveillance Program.
Methods:
A total of 3,645 Enterobacterales isolates were consecutively collected from 32 European hospitals located in 18 countries during 2020. Susceptibility testing was performed using the broth microdilution method. Cefiderocol was tested in iron-depleted cation-adjusted Mueller-Hinton broth. CLSI/FDA and EUCAST (2020) breakpoints were used. Cefiderocol breakpoints for CLSI and FDA are <=4/8/>=16 mg/L and EUCAST breakpoints are <=2/-/>2 mg/L. CRE were identified as having an MIC >2 mg/L to at least 1 carbapenem. Other agents tested included the beta-lactam/beta-lactamase inhibitor (BL/BLI) combinations: ceftazidime-avibactam, imipenem-relebactam, and meropenem-vaborbactam as well as meropenem and imipenem.
Results:The most common species was Escherichia coli (n=1,648) followed by Klebsiella pneumoniae (n=758). The CRE rate was 3.0% (108/3,645), 88% (95/108) were K. pneumoniae. The majority of isolates were from bloodstream infections (n=1,287), followed by UTI (n=1,107). The susceptibilities and MIC50/90 of cefiderocol and comparators for all isolates and isolate groups are shown in the table. The susceptibilities of all tested agents were >94% against all isolates. For the resistant phenotypes, cefiderocol was the most active agent tested. Against CRE, cefiderocol had higher susceptibility (97.2/88.9%, CLSI/EUCAST) than the BL/BLI combinations, for which susceptibilities ranged from 59.3/67.6% for imipenem-relebactam to 77.8/77.8% ceftazidime-avibactam. Cefiderocol maintained activity against isolates resistant to the BL/BLI combinations, including ceftazidime-avibactam-resistant isolates.
Conclusions:Cefiderocol had broad activity against European Enterobacterales isolates, including those resistant to recently approved BL/BLI combinations. These data suggest that cefiderocol is an important option for the treatment of infections caused by CRE and other resistant pathogens.
Keyword(s): CRE, cefiderocol, European surveillanceCOI Institutional Grants: Yes
COI Other: This study was performed by JMI Laboratories and supported by Shionogi, which included funding for services related to preparing this abstract.
Session Type: ePosters
Session Title: ePosters
Authors(s): D. Shortridge, J.M. Streit, R.E. Mendes, M. Castanheira
Authors Affiliations(s): JMI Laboratories, United States
Background:
Cefiderocol is a novel siderophore-conjugated cephalosporin with broad activity against Gram-negative bacteria. Cefiderocol was recently approved by the EMA for the treatment of infections caused by Gram-negative bacteria in adult patients with limited treatment options and by the FDA for complicated urinary tract infection (UTI), hospital-acquired bacterial pneumonia, and ventilator-associated bacterial pneumonia. Carbapenem-resistant Enterobacterales (CRE) isolates have disseminated worldwide and present a challenge to treatment. In this study, we analyzed the susceptibility of cefiderocol and comparators tested against European Enterobacterales isolates, including CRE, collected in 2020 as a part of the SENTRY Antimicrobial Surveillance Program.
Methods:
A total of 3,645 Enterobacterales isolates were consecutively collected from 32 European hospitals located in 18 countries during 2020. Susceptibility testing was performed using the broth microdilution method. Cefiderocol was tested in iron-depleted cation-adjusted Mueller-Hinton broth. CLSI/FDA and EUCAST (2020) breakpoints were used. Cefiderocol breakpoints for CLSI and FDA are <=4/8/>=16 mg/L and EUCAST breakpoints are <=2/-/>2 mg/L. CRE were identified as having an MIC >2 mg/L to at least 1 carbapenem. Other agents tested included the beta-lactam/beta-lactamase inhibitor (BL/BLI) combinations: ceftazidime-avibactam, imipenem-relebactam, and meropenem-vaborbactam as well as meropenem and imipenem.
Results:The most common species was Escherichia coli (n=1,648) followed by Klebsiella pneumoniae (n=758). The CRE rate was 3.0% (108/3,645), 88% (95/108) were K. pneumoniae. The majority of isolates were from bloodstream infections (n=1,287), followed by UTI (n=1,107). The susceptibilities and MIC50/90 of cefiderocol and comparators for all isolates and isolate groups are shown in the table. The susceptibilities of all tested agents were >94% against all isolates. For the resistant phenotypes, cefiderocol was the most active agent tested. Against CRE, cefiderocol had higher susceptibility (97.2/88.9%, CLSI/EUCAST) than the BL/BLI combinations, for which susceptibilities ranged from 59.3/67.6% for imipenem-relebactam to 77.8/77.8% ceftazidime-avibactam. Cefiderocol maintained activity against isolates resistant to the BL/BLI combinations, including ceftazidime-avibactam-resistant isolates.
Conclusions:Cefiderocol had broad activity against European Enterobacterales isolates, including those resistant to recently approved BL/BLI combinations. These data suggest that cefiderocol is an important option for the treatment of infections caused by CRE and other resistant pathogens.
Keyword(s): CRE, cefiderocol, European surveillanceCOI Institutional Grants: Yes
COI Other: This study was performed by JMI Laboratories and supported by Shionogi, which included funding for services related to preparing this abstract.
Session Type: ePosters
Session Title: ePosters
Authors(s): D. Shortridge, J.M. Streit, R.E. Mendes, M. Castanheira
Authors Affiliations(s): JMI Laboratories, United States
Background:
Cefiderocol is a novel siderophore-conjugated cephalosporin with broad activity against Gram-negative bacteria. Cefiderocol was recently approved by the EMA for the treatment of infections caused by Gram-negative bacteria in adult patients with limited treatment options and by the FDA for complicated urinary tract infection (UTI), hospital-acquired bacterial pneumonia, and ventilator-associated bacterial pneumonia. Carbapenem-resistant Enterobacterales (CRE) isolates have disseminated worldwide and present a challenge to treatment. In this study, we analyzed the susceptibility of cefiderocol and comparators tested against European Enterobacterales isolates, including CRE, collected in 2020 as a part of the SENTRY Antimicrobial Surveillance Program.
Methods:
A total of 3,645 Enterobacterales isolates were consecutively collected from 32 European hospitals located in 18 countries during 2020. Susceptibility testing was performed using the broth microdilution method. Cefiderocol was tested in iron-depleted cation-adjusted Mueller-Hinton broth. CLSI/FDA and EUCAST (2020) breakpoints were used. Cefiderocol breakpoints for CLSI and FDA are <=4/8/>=16 mg/L and EUCAST breakpoints are <=2/-/>2 mg/L. CRE were identified as having an MIC >2 mg/L to at least 1 carbapenem. Other agents tested included the beta-lactam/beta-lactamase inhibitor (BL/BLI) combinations: ceftazidime-avibactam, imipenem-relebactam, and meropenem-vaborbactam as well as meropenem and imipenem.
Results:The most common species was Escherichia coli (n=1,648) followed by Klebsiella pneumoniae (n=758). The CRE rate was 3.0% (108/3,645), 88% (95/108) were K. pneumoniae. The majority of isolates were from bloodstream infections (n=1,287), followed by UTI (n=1,107). The susceptibilities and MIC50/90 of cefiderocol and comparators for all isolates and isolate groups are shown in the table. The susceptibilities of all tested agents were >94% against all isolates. For the resistant phenotypes, cefiderocol was the most active agent tested. Against CRE, cefiderocol had higher susceptibility (97.2/88.9%, CLSI/EUCAST) than the BL/BLI combinations, for which susceptibilities ranged from 59.3/67.6% for imipenem-relebactam to 77.8/77.8% ceftazidime-avibactam. Cefiderocol maintained activity against isolates resistant to the BL/BLI combinations, including ceftazidime-avibactam-resistant isolates.
Conclusions:Cefiderocol had broad activity against European Enterobacterales isolates, including those resistant to recently approved BL/BLI combinations. These data suggest that cefiderocol is an important option for the treatment of infections caused by CRE and other resistant pathogens.
Keyword(s): CRE, cefiderocol, European surveillanceCOI Institutional Grants: Yes
COI Other: This study was performed by JMI Laboratories and supported by Shionogi, which included funding for services related to preparing this abstract.